TX-SOFTSERVE
12.7.2022 13:07:09 CEST | Business Wire | Press release
SoftServe , a leading digital authority and consulting company, has been named a Major Contender by Everest Group's Healthcare Payer Digital Services PEAK Matrix® Assessment 2022. The recognition marks the first year that SoftServe has participated in Everest Group's annual healthcare payer digital services marketplace assessment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712005092/en/
"Being named as a Major Contender in Everest Group's PEAK Matrix for Healthcare Payer Digital Services acknowledges SoftServe's significant digital healthcare experience," said Adam Gabrault, President, Strategic Verticals & Industry Solutions, North America at SoftServe. "It demonstrates how we accelerate outcomes across the healthcare continuum by providing our clients with innovative solutions and deep domain expertise."
Everest Group's Healthcare Payer Digital Services PEAK Matrix Assessment analyzes the relative market impact and overall capabilities of 26 service and technology providers. The report focuses on market size and growth, digital service themes for healthcare payers, and assessments of capabilities and market success-related dimensions. In addition, Everest Group offers independent remarks on these service providers.
SoftServe was recognized as a Major Contender by demonstrating its next-generation healthcare services delivery capabilities with the company's Human360® Member Digital Experience Platform. The member-centric solution enhances data aggregation, engagement, and care management. Everest Group highlighted SoftServe's ability to leverage its strategic partner ecosystem to augment and manage data. The report also notes SoftServe's positive client feedback on price flexibility, technical expertise, and client management.
"Business themes such as payer-provider collaboration, interoperability, value-based care, and member experience are driving the demand for digital adoption among payers,” said Chunky Satija, Vice President at Everest Group. “Along with its strategic focus of enhancing its digital capabilities through COEs and a strong partner ecosystem, SoftServe is also augmenting its vertical capabilities by building healthcare native IPs, such as DataMask solution and Member Digital Experience platform, to drive value for clients. SoftServe’s strong technical expertise and delivery excellence coupled with its focus on providing innovative price constructs has enabled it to be positioned as a Major Contender in Healthcare Payer Digital Services PEAK Matrix® Assessment 2022."
View an extract of the Healthcare Payer Digital Services PEAK Matrix Assessment 2022 here .
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize how enterprises and software companies do business. Our end-to-end solutions and expertise deliver innovation, quality, and speed across the healthcare, retail, energy, manufacturing, and financial services verticals. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s marketplace—no matter where you are in your journey.
Visit our website , blog , LinkedIn , Facebook , and Twitter .
For additional background on the work SoftServe has done to be named a Major Contender in the healthcare payer digital services marketplace, please come to our Healthcare & Life Sciences page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005092/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom